

# Inhaler development with PDGFR small molecule inhibitors for pulmonary arterial hypertension



CARDIOVASCULAR	Candidate
Product Type	Small molecule (Kinase inhibitor)
Indication	Pulmonary Arterial Hypertension (PAH)
Target	PDGFR
MoA(Mechanism of Action)	Inhibition of PDGFR shifts pulmonary arterial smooth muscle cells (PASMC) from synthetic phenotype to contractile phenotype for the treatment of PAH.
Competitiveness	1. Seralutinib: Dry Powder Inhaler (DPI), Phase II, Gossamer Bio 2. AV-101: Imatinib DPI, Phase II and III, Aerovate 3. AER-901: Solubilized imatinib for nebulizer, Phase I, Aerami VRN13 is distinguished by sparing VEGFR and securing equipotency across PDGFR isotypes.
Development Stage	Candidate
Route of Administration	Inhalation